Novo Nordisk says Metsera bid won't raise antitrust issues
03/11/2025 16:15
Corrects to remove garble in paragraph 1 COPENHAGEN, Nov 3 (Reuters) - Denmark's Novo Nordisk NOVOb.CO said on Monday it is confident that its proposed takeover of U.S. drug maker Metsera MTSR.O does not raise any antitrust issues. (Reporting by Jacob Gronholt-Pedersen and Essi Lehto, editing by Terje Solsvik) ((soren.jeppesen@thomsonreuters.com; Mobile: +45 2332 5113))
Recent news on Metsera
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up